Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28199310 | 0.83 | MAPT (0.50) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL8051337 | 0.83 | SMN1; SMN2 (0.70) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL20278348 | 0.82 | MAPT (0.57) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL1687863 | 0.82 | ALDH1A1 (0.64) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL5630152 | 0.82 | KMT2A (0.60) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL13831355 | 0.80 | RAB9A (0.39) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL9234729 | 0.80 | MAPT (0.55) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| Ethyne SCHEMBL8050785 | 0.79 | SMN1; SMN2 (0.64) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A | |
| SCHEMBL16057598 | 0.78 | PTPN1 (0.63) | RAB9ANPC1THRATHRB | |
| SCHEMBL2643703 | 0.78 | LOXL2 (0.57) | MAPTSMN1; SMN2L3MBTL1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-59190982-A | — | — | None | — | — | JP | disclosed |
| EP-2968275-B1 | LXR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20160304499-A1 | LXR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2013166037-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF EYE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-11-07 | — | — | WO | disclosed |
| JP-S59190982-A | 4'-FLUOROMETHYL-3-AMINO-2-METHYL-SUBSTITUTED PROPIOPHENONE DERIVATIVE | HOKURIKU SEIYAKU CO LTD | 1984-10-29 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304499-A1 | LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MAPT 3581/4885SMN1; SMN2 4731/4885L3MBTL1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.